BTK and Waldenstrom macroglobulinemia: A Bruton tyrosine kinase (BTK) inhibitor and hematopoietic cell kinase (HCK) inhibitor are used in the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom’s macroglobulinemia.